Arch Oncology
Biotechnology ResearchCalifornia, United States11-50 Employees
Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. Our lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, we are advancing a pipeline of antibody programs for the treatment of cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. AO-176 works by blocking the “don’t eat me” signal for macrophages, the standard mechanism of anti-CD47 antibodies. However, beyond blocking this signal, AO-176 has additional mechanisms including both directly killing tumor cells and inducing DAMPs (Damage Associated Molecular Patterns) resulting in Immunogenic Cell Death. Importantly, AO-176 binds preferentially to CD47 on tumor cells, instead of normal cells, and binds even more potently in low pH conditions such as the tumor microenvironment. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch.
1-888-653-2347 
support@leadiq.com 
